Immunosuppressive agents for dermatological indications in the ongoing COVID-19 pandemic: Rationalizing use and clinical applicability

Ananta Khurana | Snigdha Saxena

Department of Dermatology, Dr Ram Manohar Lohia Hospital and PGIMER, New Delhi, India

Correspondence
Ananta Khurana, Department of Dermatology, Dr Ram Manohar Lohia Hospital and PGIMER, New Delhi, India.
Email: drananta2014@gmail.com

Abstract
The ongoing COVID-19 epidemic has brought to the fore many concerns related to use of immunosuppressive agents (ISAs) in dermatology. While it is unclear whether the patients on ISAs for skin conditions are more prone to develop COVID-19, and what impact the ISA may have on the clinical outcome if a patient does get infected, rationalizations based on the specific immune effects of each drug, and existing literature on incidence of various infections with each, are possible. In this review, we provide the readers with practically useful insights into these aspects, related to the conventional ISAs, and briefly mention the clinical outcome data available on related scenarios from other patient groups so far. In the end, we have attempted to provide some clinically useful points regarding practical use of each dermatologically relevant conventional ISA in the current scenario.

KEYWORDS
azathioprine, ciclosporine, COVID-19, cyclophosphamide, dermatology, immunology, immunosuppressive, methotrexate, mycophenolate, pathogenesis, steroids

Immunosuppressive agents (ISA) are frequently used in dermatology practice. Increased predisposition to infections and worse outcome when one is contracted, are logical concerns with their use. In the ongoing pandemic of Coronavirus disease 2019 (COVID-19), these concerns are being increasingly discussed and amidst the lack of clarity among dermatologists, dermatology associations across the world are trying to formulate some basic guidelines on continued/new use of ISAs during the pandemic.

The purpose of this review is to analyze the infection predisposition potential of conventional ISAs used in dermatology practice, based on both mechanistic and clinical data, and the outcome data so far available on COVID-19 infection in patients on ISAs, to help the clinicians in making rational decisions for their patients.

The causative agent of COVID-19 is SARS-CoV 2, a novel β-coronavirus, which enters cells using the angiotensin-converting enzyme 2 (ACE2) receptor.\(^1\)\(^2\) The virus most likely originated in bats and has adapted to nonbat ACE2 variants as it crossed species to infect humans.\(^3\) ACE2 is expressed in many tissues including nasal mucosa, bronchus, lung, heart, esophagus, kidney, stomach, bladder, and ileum, which are consequentially vulnerable to SARS-CoV-2.\(^4\) The initial replication occurs in the mucosal epithelium of the upper respiratory tract where the virus gains entry most likely via respiratory droplets or fomite contact. Further replication occurs in lower respiratory mucosa and possibly in the gastrointestinal mucosa after which a mild viremia develops.\(^5\)\(^6\) The innate immune response is first activated mainly via pattern recognition receptors (PRR) which results in the secretion of type 1 interferons and other inflammatory cytokines. Lymphopenia is a common feature in severe infections with drastically reduced CD4+ T cells, CD8+ T cells, B cells, and natural killer (NK) cells and a reduced percentage of monocytes, eosinophils, and basophils.\(^7\) The circulating CD4+ and CD8+ T cells are in a state of "excessive activation."\(^8\) The protective role of SARS-CoV-2 IgM and IgG is unclear, with very high levels reported in severely affected patients, possibly pointing to a role of antibody-dependent enhancement (ADE) of infection.\(^9\)\(^10\) A "cytokine storm" with excessive release of proinflammatory cytokines including IL-6, IL-1β, IL-2, IL-8, IL-17, G-CSF, GM-CSF, IP10, MCP1,
| Drug          | Effects on host immune response                                                                 | Literature regarding infection risk                                                                 |
|--------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Methotrexate | • Induces apoptosis of activated T cells                                                            | • Observational studies: inconsistent results; none \(^{15}\) to increased risk \(^{16-18}\)            |
|              | • Modulates cytokine secretion from T-helper cells: increasing IL-4, IL-10 and reducing INF-\(\gamma\) and IL-2 (reduction in Th1 response) | • Systematic meta-analysis: Small but significant increased risk of all infections (but not serious infections) in RA, but no increased risk of infections in non-RA indications (psoriasis and psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic sclerosis (SSc), and Crohn's disease) \(^{39}\) |
|              | • Inhibits production of pro-inflammatory cytokines (TNF-\(\alpha\), IL-6) and enhances production of anti-inflammatory cytokines (IL-10) | • No increased risk of total or serious infections in non-RA inflammatory rheumatic diseases including psoriasis \(^{19}\) |
|              | • Increased adenosine release also increases secretion of anti-inflammatory cytokine IL-10 and inhibits production of TNF-\(\alpha\), IL-6, and IL-8 \(^{14}\) |                                                                                                       |
| Ciclosporine | • Selective action on T lymphocytes (mainly helper and suppressor subsets) \(^{20}\)             | • Low dose ciclosporine (mean 2.6 mg/kg/day) for dermatological indications: no serious infections \(^{21}\) |
|              | • Decreased IL-2 production                                                                        | • Psoriatic cohort of 2845 patients: risk of infections higher than Methotrexate \(^{22}\)            |
|              | • Reduced activity of NK cells                                                                     | • No infections reported on use as a single agent in a cohort of recalcitrant urticaria \(^{23}\)      |
|              | • Reduced INF-\(\gamma\) production \(^{13}\)                                                     | • Associated with increased risk of viral warts and Epstein Barr Virus (EBV) reactivations in transplant patients on ciclosporine based regimens \(^{24}\) |
|              |                                                                                                  | • Increased risk of CMV infection reported in transplant recipients and ulcerative colitis (reactivation) receiving ciclosporine \(^{25,26}\) |
|              |                                                                                                  | • Other infections reported with use in ulcerative colitis (high dose intravenous administration ± other ISAs): Pneumocystis carinii pneumonia, aspergillosis infection, Nocardia lung abscess \(^{27}\) |
|              |                                                                                                  |                                                                                                       |
| Cyclophosphamide | • Noncell cycle specific antimetabolite                                                               | • Opportunistic infections may develop without leukopenia, although incidence increases with increasing severity and the duration of leucopenia (increased risk with TLC \(\leq 3000/\mu l\)) \(^{32}\) |
|              | • Rapid immunosuppressive action                                                                      | • Infections noted with use in immunobuloses disorders (as adjuvant to oral steroids) \(^{24}\)      |
|              | • Depressive action on both humoral and cell-mediated immunity \(^{28,29}\)                         | • Common: bacterial infection of involved skin, transient oral candidiasis, upper respiratory tract infections |
|              | • Toxicity to immune cells: B cells>T suppressor cells>T helper cells \(^{30,31}\)                  | • Less common: intravenous line infection, community-acquired pneumonia, viral pneumonitis, septic bacterial bursitis, uni/multi dermatomal herpes zoster, candidal balanoposthitis, vaginal candidiasis, reactivation of tuberculosis \(^{33,34}\) |
|              | • B cells remained low at 1 year following 6 cycles of pulsed IV cyclophosphamide \(^{31}\)         | • Nonsignificant increase in incidence of infections (minor) with intravenous pulse cyclophosphamide combined with oral steroids for pemphigus vulgaris \(^{35}\) |
|              |                                                                                                  | • In lupus nephritis patients, addition of cyclophosphamide to steroids does not increase risk of infections over use of steroid alone, except for localized herpes zoster \(^{36,37}\) |
|              |                                                                                                  | • Pulse cyclophosphamide, when used without daily oral cyclophosphamide, has been associated with lower risk of leucopenia and infections \(^{38}\) |
| Azathioprine | • Suppresses function of T cells, B cells, antigen presenting cells, and natural killer cells \(^{14}\) | Infections reported with dermatological use as adjuvant to steroids: Herpes zoster, oral candidiasis, dermatophytoses, cellulitis, upper respiratory infections, pneumonia, tuberculosis \(^{39}\) |
|              |                                                                                                  | As an isolated agent:                                                                                  |
|              |                                                                                                  | • No infections reported in a cohort of 40 cases treated for urticaria                                   |
|              |                                                                                                  | • 12 of 46 patients of airborne contact dermatitis developed skin infections (furunculosis-7, herpes labialis-1, herpes zoster-1, scabies-1, tinea corporis-2) and one developed tuberculosis \(^{23}\) |
|              |                                                                                                  | Inflammatory bowel disease cohorts: nonsignificant difference in infections compared with controls (Viral: CMV, EBV, Varicella zoster; Bacterial: E. coli osteomyelitis, Listeria monocytogenes, Nocardia, Salmonella, and Staphylococcal, pneumonia, urinary tract infection, and sepsis) \(^{40,41}\) |
|              |                                                                                                  | Lymphopenia \(<600/\mu l\) increases the risk for development of infection \(^{42}\)                  |
TABLE 1  (Continued)

| Drug                        | Effects on host immune response                                                                 | Literature regarding infection risk                                                                 |
|-----------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| Mycophenolate mofetil      | Inhibits T and B lymphocyte responses, including mitogen and mixed lymphocyte responses        | As adjuvant to steroids in pemphigus (dose 2-3 g), infections reported include: Candidal mucocutaneous infections (10%), herpes (2%), molluscum (2%), tinea (3%), upper/lower respiratory tract (5%/3%), urinary tract infection (5%), skin and soft tissue infections (5%), viral (2%) (at least one infection in 21% patients)43 An increased susceptibility to viral infections, especially herpes, has been noted: herpes zoster occurs with incidence figures of 2% to 10% in psoriasis,44 20% in atopic dermatitis45 and 6% in liver transplant recipients,46 although the viral infections noted have not been of increased severity or duration44,46 |
| Corticosteroids             | Profound effects on both innate and adaptive immune response. Immune cells suppressed: all subsets of lymphocytes (B cells at higher doses than T cells), mast cells, monocytes, eosinophils, basophils, neutrophils, macrophages, antigen presenting cells Repressed signal transduction pathways (NFKB, AP-1) leading to reduced production of various cytokines and inflammatory mediators Risk of some bacterial, viral, and fungal infections 2- to 6-fold higher in those on oral glucocorticoids compared to age, gender, and the underlying disease matched controls57 Large population-based cohort study: baseline steroid use associated with increased long-term risks of community-acquired infections and sepsis (adjusted OR for sepsis-2.11)48 Increased risk of serious bacterial infections with as low as 5 mg prednisolone equivalent for 1 week41 Infection risk is dose and duration dependent with stepwise increase in the risk of serious bacterial infections with increasing dose and duration Risk of serious bacterial infections higher for current exposure to corticosteroids compared with other DMARDS49 Risk for Lower Respiratory Tract Infection and local candidiasis highest during the first week of exposure and decreases thereafter while the risk remains stable throughout exposure for herpes zoster, bloodstream infections, and cellulitis37 Increased risk of opportunistic infections including Pneumocystis jiroveci pneumonia, aspergillosis, nontuberculous mycobacterial disease, candidiasis, cryptococcosis, strongyloidiasis50 Risks of infection increases with age and is higher in diabetics, with higher doses, and lower plasma albumin level47 |

MIP1α, and TNF occurs in severe cases causing extensive tissue damage in lungs and other organs.11,12 Thus, an uncontrolled activation of the innate immune response, along with an impaired adaptive immune response, characterize severe disease.7

The antiviral host response largely depends on cytotoxic T lymphocytes, NK cells, antibody-dependent cellular cytotoxicity and certain cytokines, prominently interferons. NK cells mediate immunity to viral pathogens directly through the cytolysis of virally infected tissues or indirectly by elaborating inflammatory cytokines, such as interferons (IFNs).12 The major ISAs used in dermatology act on various aspects of the host immunity, and mainly on adaptive immune responses. It is theoretically plausible that the “cytokine storm” that occurs in severe COVID-19 cases may be mitigated by some ISAs, although clinical relevance of this is pending trials. Further, the concern of mitigating viral replication by effective host immune response takes precedence over the ameliorating the cytokine storm that may only arise in a small proportion of cases. Before we delve further into which drugs may be potentially more harmful than the others, it is pertinent to recapitulate the immune effects of the major ISAs used in dermatology and their infection risk (Table 1).

Broadly, oral glucocorticoids extensively affect the various immune pathways and cells, and can precipitate a broad spectrum of bacterial, fungal and viral infections in those on chronic treatment, and even with short term use of low doses.51 Steroids have been used to suppress the “cytokine storm” occurring in severe SARS CoV-2 infection, however, the safety, utility, and timing of administration are not clearly defined.52 Cyclophosphamide is a rapidly acting immunosuppressive suppressing both cellular and humoral immunity. The drug, at low doses, preferentially depletes T regulatory cells while enhancing effector T cell function mainly CD8+ cytotoxic T lymphocytes. The NK cell response is also augmented by cyclophosphamide.53 Thus, antiviral responses may not be affected at low doses. The risk of infective complications probably increases with development of leucopenia, although the infections reported in dermatological literature are mostly non serious13 (Table 1). It is notable that the risk of leucopenia and infective complications is lower with pulsed cyclophosphamide than with daily oral cyclophosphamide.54 However, in dermatological conditions, pulse cyclophosphamide is generally combined with daily oral cyclophosphamide (given in between the pulses), thus offsetting any advantage of pulse cyclophosphamide on that account.30

Ciclosporine has a more specific action on T lymphocytes but also shows some depression of innate response via effect on NK cells.13 It inhibits both T-helper cells and precursors of cytotoxic T lymphocytes, while sparing the T suppressor cell induction.55 The inhibition of both
NK cells and cytotoxic T cells is perhaps a reason for viral infections developing with ciclosporine use. Animal models have demonstrated an inability to mount an effective immune response to viral infections including Cytomegalovirus (CMV), influenza, and Herpes Simplex Virus-2 (HSV-2) with administration of ciclosporine although paradoxically the drug has been shown to inhibit MERS-CoV replication in cell culture.\textsuperscript{20,56} Also, viral infections with cyclosporine are largely reported with its use in nondermatological indications, mainly in transplant recipients and ulcerative colitis. Mycophenolate mofetil has a more profound effect on effector T cells than ciclosporine and also suppresses NK cells, possibly accounting for the high incidence of cutaneous viral infections with mycophenolate mofetil, although the drug has a low infection risk otherwise.\textsuperscript{57,58} Azathioprine has also demonstrated in vitro activity against NK cells and has a substantial effect on antibody-dependent cell-mediated cytotoxicity, thus interfering with antiviral immune responses.\textsuperscript{59} Although, when used alone for dermatological indications, the drug has mainly been associated with cutaneous bacterial and viral infections and infestations mainly (Table 1).

Interestingly, mycophenolic acid and 6-thioguanine have been found to have potent activity against coronaviruses in vitro assays.\textsuperscript{60,61} Methotrexate (MTX) has a good safety record with robust literature support on lack of any significant infection risk for use in nonrheumatoid arthritis (RA) indications. The respiratory adverse effects of MTX have been a cause of concern, especially in RA patients. However, MTX related pneumonitis is rarer than previously thought and importantly, MTX use in psoriasis and psoriatic arthritis is not associated with any significant increase in respiratory adverse events as per a recent meta-analysis.\textsuperscript{38,62}

Although, the data on incidence of COVID-19 in patients on ISAs and their clinical outcomes is scarce as yet (Table 2), some clarity may

| TABLE 2 | Summary of literature regarding patients on chemotherapeutic/immunosuppressive/imunomodulatory medications who developed COVID-19 |
|---------|----------------------------------------------------------------------------------------------------------------|
| **Rheumatology** | **Authors** | **Patient profile** | **Drugs** | **Outcome of COVID-19** |
| Monti et al\textsuperscript{63} | Chronic arthritis RA-3, SpondyloArthritis (SpA)-1 | Methotrexate: 2 Leflunomide: 1 Etanercept: 2 Abatacept: 1 Low dose steroids: 2 (<5 mg/day prednisolone equivalent) Tofacitinib: 1 | Hospital admission required: 1 |

| **Onco** | **Authors** | **Patient profile (patients on active treatment for cancer at the time of COVID diagnosis)** | **Drugs** | **Outcome of COVID-19** |
| Liang et al\textsuperscript{64} | Four—Lung adenocarcinoma One—Chromophobe renal cell carcinoma One—Papillary thyroid microcarcinoma (age range: 47-63 years) | Two on chemotherapy for advanced cancer Two on targeted therapy One on TSH inhibition therapy One—recurrence, on immunotherapy (further details not mentioned) | Severe disease in two of six (one on chemotherapeutic drugs and one on immunotherapy) (Ages: 58 and 63 years) |
| Yu et al\textsuperscript{65} | Five patients of non-small cell lung cancer | Combinations of: Carboplatin, Pembrolizumab, Pemetrexed, Docetaxel, Cisplatin, Osimertinib, Sintilimab | Severe disease—one (on pemetrexed, cisplatin, and radiotherapy) (Age not mentioned) |

| **Transplant recipients** | **Authors** | **Patient profile** | **Drugs** | **Outcome of COVID-19** |
| Gandolfini et al\textsuperscript{66} | Two renal transplant recipients (75 and 52 years of age) | Tacrolimus Mycophenolate mofetil Steroids | Survived—One Died—One |
| Huang et al\textsuperscript{67} | One renal transplant patient (58 years of age) One Bone marrow transplant recipient (51 years of age) | Mycophenolate mofetil Steroids Ciclosporine | Died Died |
be gained from data on other viral respiratory infections and previous influenza and corona virus epidemics. Use of ISAs was not listed as a risk factor for primary MERS-CoV infection during the outbreak in middle eastern countries. However, persons with chronic medical conditions which included those on ISAs were found to be more vulnerable to clinically defined SARS in the SARS-CoV outbreak in China in 2003. A large retrospective cohort study involving 46 030 rheumatoid arthritis patients found a higher incidence of influenza in this group but with no effect of disease-modifying antirheumatic drugs—DMARDs (including azathioprine, cyclophosphamide, ciclosporine, and methotrexate) or biologic use on the incidence rate. Similarly, for complications, the incidence rates did not depend on whether or not DMARDs or biologics were being taken. However, systemic steroid use has been shown to be a risk factor for developing severe influenza. D’Antiga shared their preliminary experience among patients in follow-up for cirrhosis, transplantation, autoimmune liver disease, chemotherapy for hepatoblastoma at the Hepatology, Gastroenterology and Transplantation center in the “red zone” of the Italian outbreak, stating that none of their patients developed a clinical pulmonary disease, despite some testing positive for SARS-CoV-2 and suggesting that immunosuppressed patients may not be at increased risk of severe pulmonary disease compared to the general population. However, there is no data yet on the incidence of SARS-CoV-2/other respiratory viral illnesses in cohorts of dermatology patients on ISAs, leaving interpretations to extrapolations from the available literature from other conditions, although dermatology patients on ISAs would generally be overall healthier compared to rheumatological, oncological or transplant patients on ISAs and hence likely far better than the other reported groups.

Interestingly, MTX has been shown not to affect the immunogenicity of trivalent influenza vaccine given to RA patients while continuing the drug, though the same is reduced in patients treated with anti-TNF agents. Similarly, no difference in antibody titers, compared with healthy controls, was detected after influenza vaccination among transplant recipients on azathioprine, while response was reduced by ciclosporine and mycophenolate mofetil. This is likely related to the differential effects of these drugs on humoral immune response but is unlikely to be of much significance to the primary host response to the virus during a natural infection.

Lastly, from the scant clinical outcome data on patients on ISAs developing COVID-19 (Table 2), it can be seen that among rheumatological patients on DMARDs, outcome was not different from what is otherwise expected from available literature on COVID-19 so far. From among oncological and transplant recipients on ISAs infected with COVID-19, severe infection and mortality seems to have occurred especially in older ages patients. Older age has otherwise too emerged as a significant risk factor for severe COVID-19 disease and mortality. Further, transplant and oncology patients are generally on multiple ISA drugs and may have poorer general health status than dermatology patients on ISAs.

To conclude, there is little evidence so far to support a presumption of a higher incidence and greater severity of COVID-19 in dermatological patients on ISAs. Awaiting further data, however, a few broad points may be taken into consideration to reduce the supposed impact of the disease on dermatology patients requiring ISAs, and these are listed below:

1. Sudden shifts in drugs and doses must be avoided to prevent flare of underlying diseases. In case, a patient on steroids/other conventional ISAs develops laboratory confirmed COVID-19, the decision to reduce dose/withhold the drug must be based on the severity of the underlying dermatological disease. For example, in case of a recalcitrant and severe pemphigus vulgaris patient, sudden interruption of treatment may itself be life threatening. On the other hand, in a stable well-controlled patient of psoriasis, interruption of treatment till recovery of COVID-19 is a practically feasible option. However, oral steroids should never be suddenly interrupted when they have been in use for long.

2. The dose of oral steroids should be kept at a minimum level required for disease control.

3. Keep a close watch on total leucocyte and lymphocyte counts for patients on azathioprine and cyclophosphamide, as infection risk with these has been shown to be associated with lower counts.

4. Methotrexate has strong literature to support its use as there is low infection risk in non-RA conditions. Hence it may be the preferred conventional ISA in these times and can be used in standard dermatological doses.

5. Ciclosporine use has been associated with development of severe viral infections in nondermatological patients and hence cautious use is advised. Drug interactions also need to be considered while using antimicrobials in infected patients already on ciclosporine.

6. Standard measures for prevention of COVID-19 via droplet and fomite contact must be emphasized to patients.

ORCID
Ananta Khurana https://orcid.org/0000-0001-7020-7777
Snigdha Saxena https://orcid.org/0000-0002-9665-7853

REFERENCES
1. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.
2. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-273.
3. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science. 2004;303:1666-1669.
4. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14:185-192.
5. Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:E372.
6. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-1833.e3.
7. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20:269-270.
8. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420-422.

9. Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv 2020.03.12.20035048.

10. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 Mar 28.

11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.

12. Shi Y, Tan M, Chen X, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. medRxiv 2020.03.12.20034736.

13. Wang H, Grzywacz B, Sukovic D, et al. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood. 2007;110:1530-1539.

14. Sekhri R, Sekhri V, Sardana K. Immunosuppressive drugs. In: Sardana K, ed. Systemic Drugs in Dermatology. New Delhi, India: Jaypee; 2016:304-385.

15. Lacaille D, Guh DP, Abramowicz M, Anis AH, Esdaille JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1074-1081.

16. van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994;53:224-228.

17. LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med. 1994;150:258-260.

18. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum. 1995;24:411-421.

19. Ibrahim A, Ahmed M, Conway R, Carey JJ. Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis. J Clin Med. 2018;7(1):5.

20. Kim JH, Perfect JR. Infection and cyclosporine. Rev Infect Dis. 1989;11:677-690.

21. Choi E, Cook A, Phuan C, et al. Outcomes of prolonged and low-dose ciclosporin in an Asian population. J Dermatolog Treat. 2019 Sep;10:1-6.

22. Daudén E, Carretero G, Rivera R, et al. Long term safety of nine systemic medications for psoriasis: a cohort study using the Biobadaderm Registry. J Am Acad Dermatol. 2020;80(1):3045-30455.

23. Pathania VS, Bishnoi A, Parsad D, Kumar A, Kumaran MS. Comparing azathioprine with cyclosporine in the treatment of antithistamine refractory chronic spontaneous urticaria: a randomized prospective active-controlled non-inferiority study. World Allergy Organ J. 2019;12:100033.

24. Krüger-Corcoran D, Stockfleth E, Jürgensen JS, et al. Human papillomavirus-associated warts in organ transplant recipients. Incidence, risk factors, management. Hautarzt. 2010;61:220-229.

25. Hoppe L, Marroni CA, Bressane R, et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients. Transplant Proc. 2006;38:1922-1923.

26. Piton G, Dupont-Gossart A-C, Weber A, et al. Severe systemic cytomegalovirus infections in patients with steroid-refractory ulcerative colitis treated by an oral microemulsion form of cyclosporine: report of two cases. Gastroenterol Clin Biol. 2008;32:460-464.

27. Arts J, D’Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10:73-78.

28. Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Dermatol. 1984;11:1115-1126.

29. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 1991;20:194-208.

30. Fox LP, Pandya AG. Pulse intravenous cyclophosphamide therapy for dermatologic disorders. Dermatol Clin. 2000;18:459-473.

31. Dau PC, Callahan J, Parker R, Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol. 1991;18:270-276.

32. Dutz JP, Ho VC. Immunosuppressive agents in dermatology. An update. Dermatol Clin. 1998;16:235-251.

33. Cummins DL, Mimmouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment of pemphigus vulgaris and folliculitis. J Am Acad Dermatol. 2003;49:276-280.

34. Jain R, Kumar B. Immediate and delayed complications of dexamethasone cyclophosphamide pulse (DCP) therapy. J Dermatol. 2003;30:713-718.

35. Sharma VK, Khandpur S. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris. Clin Exp Dermatol. 2013;38:659-664.

36. Carette S, Klippel JH, Decker JL, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med. 1983;99:1-8.

37. Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614-619.

38. Fraguolis GE, Conway R, Nikiphorou E. Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Rheumatology (Oxford). 2019;58:1900-1906.

39. Sukhananpong S, Thongtan D, Kanokrungsee S, Suchonwatanit P, Chanprapaph K. A comparison of azathioprine and mycophenolate mofetil as adjuvant drugs in patients with pemphigus: a retrospective cohort study. Dermatol Ther (Heidel). 2020;10:179-189.

40. Aberra FN, Lichtenstein GR. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:685-695.

41. Vögelin M, Biedermann L, Frei P, et al. The impact of azathioprine-associated lymphopenia on the onset of opportunistic infections in patients with inflammatory bowel disease. PLoS One. 2016;11:e0155218.

42. Glück T, Kiefmann B, Grohmann M, Falk W, Straub RH, de la Cruz LJ, Rodrigo López JM. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation. J Hepatol. 2006;38:2480-2481.

43. Jiménez-Pérez M, Lozano Rey JM, Marín García D, Olmedo Martín R, Rodrigo López JM, Vidal del Moro F, de la Cruz R, Rodrigo López JM. Mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130:2041-2048.

44. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 1987;17:962-971.

45. Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. J Clin Aesthet Dermatol. 2008;1:107-114.

46. Chaudhary NS, Donnelly JP, Moore JX, Baddley JW, Safford MM, Wang HE. Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohort. Crit Care. 2017;21:185.
49. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 83,039 seniors with rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2013;65:353-361.

50. Youssif J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. *Rheum Dis Clin North Am*. 2016;42:157-176.

51. Dixon WG, Abramowicz M, Beauchamp M-E, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. *Ann Rheum Dis*. 2012;71:1128-1133.

52. Yuen K-S, Ye Z-W, Fung S-Y, Chan C-P, Jin D-Y. SARS-CoV-2 and COVID-19: the most important research questions. *Cell Biosci*. 2020;10:40.

53. Sharma B, Vaziri ND. Augmentation of human natural killer cell activity by cyclophosphamide in vitro. *Cancer Res*. 1984;44:3258-3261.

54. de Groot K, Harper L, Jayne DRW, et al. Pulse versus daily oral cyclosporin A or interferon-α treatment. *Ann Intern Med*. 2009;150:670-680.

55. Hess AD, Colombani PM, Esa AH. Cyclophosphamide and the immune response: basic aspects. *Crit Rev Immunol*. 1986;6:123-149.

56. de Wilde AH, Raj VS, Ouchoom D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. *J Gen Virol*. 2013;94:1749-1760.

57. Furukawa A, Wisel SA, Tang Q. Impact of immune-modulatory drugs on regulatory T cell. *Transplantation*. 2016.100:2288-2300.

58. Ohata K, Espinoza J, Llo X, Kondo Y, Nakao S. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. *Biol Blood Marrow Transplant*. 2011;17:205-213.

59. Purves EC, Berenbaum MC. Selective suppression of murine antibody-dependent cell-mediated cytotoxicity by azathioprine. *Transplantation*. 1975;19:274-276.

60. Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. *J Gen Virol*. 2014;95:571-577.

61. Chen X, Chou C-Y, Chang G-G. Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. *Antivir Chem Chemother*. 2009;19:151-156.

62. Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. *BMJ*. 2015;350:h1269.

63. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. *Ann Rheum Dis*. 2020;79:667-668.

64. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol*. 2020;21:335-337.

65. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. *JAMA Oncol*. 2020 Mar 25;e200998.

66. Gandolfi I, Delsante M, Flaccadori E, et al. COVID-19 in kidney transplant recipients. *Am J Transplant*. 2020;97(6):1076-1082.

67. Huang J, Lin H, Wu Y, et al. COVID-19 in posttransplant patients—report of 2 cases. *Am J Transplant*. 2020 Apr 3.

68. Sikkema RS, Farag EABA, Himatt S, et al. Risk factors for primary Middle East respiratory syndrome coronavirus infection in camel workers in Qatar during 2013-2014: a case-control study. *J Infect Dis*. 2017;215:1702-1705.

69. Alraddadi BM, Al-Salmi HS, Jacobs-Silfka K, et al. Risk factors for Middle East respiratory syndrome coronavirus infection among healthcare personnel. *Emerg Infect Dis*. 2016;22:1915-1920.

70. Wu J, Xu F, Zhou W, et al. Risk factors for SARS among persons without known contact with SARS patients, Beijing, China. *Emerg Infect Dis*. 2004;10:210-216.

71. Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. *BMC Musculoskelet Disord*. 2012;13:158.

72. Wu U-I, Wang J-T, Ho Y-C, Pan S-C, Chen Y-C, Chang S-C. Factors associated with development of complications among adults with influenza: a 3-year prospective analysis. *J Formos Med Assoc*. 2012;111:364-369.

73. D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. *Liver Transpl*. 2020 Mar 20.

74. Jain VK, Bhashini N, Balajecky LK, Sistia S, Parija SC, Negi VS. Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis. *Indian J Med Res*. 2017;145:464-470.

75. Kapetanovic MC, Saxne T, Nilsson J-A, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. *Rheumatology (Oxford)*. 2007;46:608-611.

76. Briggs WA, Rozek RJ, Migdal SD, et al. Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses. *Ann Intern Med*. 1980;92:471-477.

77. Azevedo LS, Gerhard J, Miraglia JL, et al. Seroconversion of 2009 pandemic influenza A (H1N1) vaccination in kidney transplant patients and the influence of different risk factors. *Transplant Int*. 2013;15:612-618.

78. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2020;41:145-151.

79. Vincent J-L, Taccone FS. Understanding pathways to death in COVID-19. *Lancet Respir Med*. 2020;8(5):430-432.

80. Wang C, Rademaker M, Baker C, Foley P. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australian/New Zealand consensus statement. *Australas J Dermatol*. 2020 Apr 7.

How to cite this article: Khurana A, Saxena S. Immunosuppressive agents for dermatological indications in the ongoing COVID-19 pandemic: Rationalizing use and clinical applicability. *Dermatologic Therapy*. 2020;33:e13639. [https://doi.org/10.1111/dth.13639](https://doi.org/10.1111/dth.13639)